Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Wisniewski, S. R. Articles by Rush, A. J. Search for Related Content PubMed Citation Articles by Wisniewski, S. R. Articles by Rush, A. J. Depression Cognitive Therapy Antidepressants Related Articles

Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report

OBJECTIVE: Treatment of major depressive disorder typically entails implementing treatments in a stepwise fashion until a satisfactory outcome is achieved. This study sought to identify factors that affect patients’ willingness to accept different second-step treatment approaches. METHOD: Participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial who had unsatisfactory outcomes after initial treatment with citalopram were eligible for a randomized second-step treatment trial. An equipoise-stratified design allowed participants to exclude or include specific treatment strategies. Analyses were conducted to identify factors associated with the acceptability of the following second-step treatments: cognitive therapy versus no cognitive therapy, any switch strategy versus any augmentation strategy (including cognitive therapy), and a medication switch strategy only versus a medication augmentation strategy only. RESULTS: Of the 1,439 participants who entered second-step treatment, 1% accepted all treatment strategies, 3% accepted only cognitive therapy, and 26% accepted cognitive therapy (thus, 71% did not accept cognitive therapy). Those with higher educational levels or a family history of a mood disorder were more likely to accept cognitive therapy. Participants in primary care settings and those who experienced a greater side effect burden or a lower reduction in symptom severity with citalopram were more likely to accept a switch strategy as compared with an augmentation strategy. Those with concurrent drug abuse and recurrent major depressive disorder were less likely to accept a switch strategy. CONCLUSIONS: Few participants accepted all treatments. Acceptance of cognitive therapy was primarily associated with sociodemographic characteristics, while acceptance of a treatment switch was associated with the results of the initial treatment.

Related Articles:

Cognitive Therapy and Interpersonal Psychotherapy: 30 Years Later

Myrna M. Weissman
Am J Psychiatry 2007 164: 693-696. [Full Text] [PDF]

This article has been cited by other articles:

				B. N. Gaynes, D. Warden, M. H. Trivedi, S. R. Wisniewski, M. Fava, and A. J. Rush What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression Psychiatr Serv, November 1, 2009; 60(11): 1439 - 1445. [Abstract] [Full Text] [PDF]

				P. J. van't Veer-Tazelaar, H. W. J. van Marwijk, P. van Oppen, H. P. J. van Hout, H. E. van der Horst, P. Cuijpers, F. Smit, and A. T. F. Beekman Stepped-Care Prevention of Anxiety and Depression in Late Life: A Randomized Controlled Trial Arch Gen Psychiatry, March 1, 2009; 66(3): 297 - 304. [Abstract] [Full Text] [PDF]

				Bibliography for Major Depressive Disorder and Suicide Focus, January 1, 2008; 6(1): 58 - 62. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us